New coils with unproven clinical benefit enlarge the armamentarium for endovascular aneurysm treatment continuously. Large patient numbers needed to detect benefits of such new techniques prevent timely evaluation of efficacy. We propose measuring the volume of aneurysm recurrences as surrogate endpoint for coil stability. We hypothesize that this method allows detecting effects of new materials with reduced sample sizes in comparison to conventional studies with dichotomous endpoints.
New coils with unproven clinical benefit enlarge the armamentarium for endovascular aneurysm treatment continuously. Large patient numbers needed to detect benefits of such new techniques prevent timely evaluation of efficacy. We propose measuring the volume of aneurysm recurrences as surrogate endpoint for coil stability. We hypothesize that this method allows detecting effects of new materials with reduced sample sizes in comparison to conventional studies with dichotomous endpoints.